Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS (ESIS)
Status
Conditions
Details and patient eligibility
About
To observe the effect of goserelin 3,6mg sc depot injection by assessment of the mean percent reduction scores for symptoms: dysmenorrhoea, dyspareunia and pelvic pain; to observe the effect of goserelin 3,6mg sc depot injection by assessment of the mean percent reduction scores for pelvic tenderness and indurations; to observe the reduction in the proportion of patients requiring analgesics for the relief of pelvic pain for 6 months in patients treated with Zoladex 3.6 mg.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- patients diagnosed with endometriosis that the doctors have already decided to treat with Zoladex within the last month, before inclusion in this program, according to Romanian approved goserelin 3,6 mg
Exclusion criteria
- patients who have a known hypersensitivity to goserelin (Zoladex) or any of its excipients or any other GnRH analogue, pregnancy, according to Romanian approved goserelin 3,6 mg SmPC
Trial design
105 participants in 1 patient group
Trial contacts and locations
There are currently no registered sites for this trial.
Timeline
Last updated: Sep 10, 2009Start date
Oct 01, 2008 • 16 years ago
Today
May 05, 2025
Sponsor of this trial
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal